{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,5,2]],"date-time":"2025-05-02T04:05:37Z","timestamp":1746158737528,"version":"3.40.4"},"reference-count":20,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,5,2]],"date-time":"2024-05-02T00:00:00Z","timestamp":1714608000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.es","elsevier.es","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cl\u00ednica e Investigaci\u00f3n en Arteriosclerosis"],"published-print":{"date-parts":[[2025,1]]},"DOI":"10.1016\/j.arteri.2024.04.004","type":"journal-article","created":{"date-parts":[[2024,6,29]],"date-time":"2024-06-29T11:20:05Z","timestamp":1719660005000},"page":"100723","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["The athero-contour: A novel tool for global and rapid assessment of atherogenic parameters. A use case in saroglitazar treatment of MAFLD patients"],"prefix":"10.1016","volume":"37","author":[{"given":"Kung-Hung","family":"Lin","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nuria","family":"Amigo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pablo","family":"Ortiz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cristina","family":"Alonso","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexander V.","family":"Smolensky","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Deven","family":"Parmar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Naga P.","family":"Chalasani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Samer","family":"Gawrieh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.arteri.2024.04.004_bib0105","doi-asserted-by":"crossref","first-page":"2122","DOI":"10.1016\/j.jacc.2020.02.059","article-title":"Triglyceride-rich lipoprotein cholesterol small dense LDL cholesterol, and incident cardiovascular disease","volume":"75","author":"Duran","year":"2020","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.arteri.2024.04.004_bib0110","doi-asserted-by":"crossref","first-page":"299","DOI":"10.3390\/medicina58020299","article-title":"Atherosclerosis development and progression: the role of atherogenic small, dense LDL","volume":"58","author":"Vekic","year":"2022","journal-title":"Medicina (Kaunas)"},{"key":"10.1016\/j.arteri.2024.04.004_bib0115","first-page":"300","article-title":"Comprehensive review of cardiovascular disease risk in nonalcoholic fatty liver disease","volume":"9","author":"Josloff","year":"2022","journal-title":"J Cardiovasc Dev Dis"},{"key":"10.1016\/j.arteri.2024.04.004_bib0120","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1093\/clinchem\/hvaa296","article-title":"Triglyceride-rich lipoprotein remnants and cardiovascular disease","volume":"67","author":"Duran","year":"2021","journal-title":"Clin Chem"},{"key":"10.1016\/j.arteri.2024.04.004_bib0125","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1016\/j.jacc.2017.12.006","article-title":"Lipids lipoproteins, and metabolites and risk of myocardial infarction and stroke","volume":"71","author":"Holmes","year":"2018","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.arteri.2024.04.004_bib0130","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1194\/jlr.D050120","article-title":"Liposcale: a novel advanced lipoprotein test based on 2D diffusion-ordered 1H NMR spectroscopy","volume":"56","author":"Mallol","year":"2015","journal-title":"J Lipid Res"},{"key":"10.1016\/j.arteri.2024.04.004_bib0135","doi-asserted-by":"crossref","first-page":"354","DOI":"10.3390\/jcm9020354","article-title":"Human serum\/plasma glycoprotein analysis by (1)H-NMR, an emerging method of inflammatory assessment","volume":"9","author":"Fuertes-Martin","year":"2020","journal-title":"J Clin Med"},{"key":"10.1016\/j.arteri.2024.04.004_bib0140","doi-asserted-by":"crossref","DOI":"10.1016\/j.jacl.2018.01.002","article-title":"Relations of GlycA and lipoprotein particle subspecies with cardiovascular events and mortality: a post hoc analysis of the AIM-HIGH trial","volume":"12","author":"Otvos","year":"2018","journal-title":"J Clin Lipidol"},{"key":"10.1016\/j.arteri.2024.04.004_bib0145","doi-asserted-by":"crossref","first-page":"e14101","DOI":"10.1111\/eci.14101","article-title":"Association between exposure to air pollution and blood lipids in the general population of Spain","volume":"54","author":"Vald\u00e9s","year":"2024","journal-title":"Eur J Clin Investig"},{"key":"10.1016\/j.arteri.2024.04.004_bib0150","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.recesp.2021.02.013","article-title":"Advanced lipoprotein profile in individuals with normal and impaired glucose metabolism","volume":"75","author":"Puig-Jov\u00e9","year":"2022","journal-title":"Rev Esp Cardiol (Engl Ed)"},{"key":"10.1016\/j.arteri.2024.04.004_bib0155","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1002\/hep.31843","article-title":"Saroglitazar, a PPAR-alpha\/gamma agonist, for treatment of NAFLD: a randomized controlled double-blind phase 2 trial","volume":"74","author":"Gawrieh","year":"2021","journal-title":"Hepatology"},{"key":"10.1016\/j.arteri.2024.04.004_bib0011","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1007\/s40261-013-0128-3","article-title":"Pharmacokinetics, safety, and tolerability of saroglitazar (ZYH1), a predominantly PPARalpha agonist with moderate PPARgamma agonist activity in healthy human subjects","volume":"33","author":"Jani","year":"2013","journal-title":"Clin Drug Investig"},{"key":"10.1016\/j.arteri.2024.04.004_bib0165","doi-asserted-by":"crossref","first-page":"4791","DOI":"10.1093\/eurheartj\/ehab551","article-title":"Triglyceride-rich lipoproteins and their remnants: metabolic insights, role in atherosclerotic cardiovascular disease, and emerging therapeutic strategies \u2013 a consensus statement from the European Atherosclerosis Society","volume":"42","author":"Ginsberg","year":"2021","journal-title":"Eur Heart J"},{"key":"10.1016\/j.arteri.2024.04.004_bib0170","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1186\/s12933-022-01726-y","article-title":"High-density lipoprotein subclasses and cardiovascular disease and mortality in type 2 diabetes: analysis from the Hong Kong Diabetes Biobank","volume":"21","author":"Jin","year":"2022","journal-title":"Cardiovasc Diabetol"},{"key":"10.1016\/j.arteri.2024.04.004_bib0175","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1016\/j.jacc.2017.12.006","article-title":"Lipids, lipoproteins, and metabolites and risk of myocardial infarction and stroke","volume":"71","author":"Holmes","year":"2017","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.arteri.2024.04.004_bib0180","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1373\/clinchem.2016.261636","article-title":"A novel protein glycan-derived inflammation biomarker independently predicts cardiovascular disease and modifies the association of HDL subclasses with mortality","volume":"63","author":"McGarrah","year":"2017","journal-title":"Clin Chem"},{"key":"10.1016\/j.arteri.2024.04.004_bib0185","doi-asserted-by":"crossref","first-page":"2099","DOI":"10.1016\/j.numecd.2021.03.021","article-title":"Quantification of glycoproteins by nuclear magnetic resonance associated with preclinical carotid atherosclerosis in patients with type 1 diabetes","volume":"31","author":"Ser\u00e9s-Noriega","year":"2021","journal-title":"Nutr Metab Cardiovasc Dis"},{"key":"10.1016\/j.arteri.2024.04.004_bib0190","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.atherosclerosis.2021.06.905","article-title":"Serum glycoproteins A and B assessed by (1)H-NMR in familial hypercholesterolemia","volume":"330","author":"Malo","year":"2021","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.arteri.2024.04.004_bib0195","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1161\/HYPERTENSIONAHA.122.20137","article-title":"Glycoprotein serum concentrations assessed by 1H-NMR are increased in patients with high blood pressure","volume":"80","author":"Andreychuk","year":"2023","journal-title":"Hypertension"},{"key":"10.1016\/j.arteri.2024.04.004_bib0200","doi-asserted-by":"crossref","first-page":"775677","DOI":"10.3389\/fendo.2021.775677","article-title":"Triglyceride-rich lipoproteins and glycoprotein A and B assessed by 1H-NMR in metabolic-associated fatty liver disease","volume":"12","author":"Moreno-Vedia","year":"2021","journal-title":"Front Endocrinol (Lausanne)"}],"container-title":["Cl\u00ednica e Investigaci\u00f3n en Arteriosclerosis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S021491682400041X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S021491682400041X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T08:38:28Z","timestamp":1746088708000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S021491682400041X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1]]},"references-count":20,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,1]]}},"alternative-id":["S021491682400041X"],"URL":"https:\/\/doi.org\/10.1016\/j.arteri.2024.04.004","relation":{},"ISSN":["0214-9168"],"issn-type":[{"type":"print","value":"0214-9168"}],"subject":[],"published":{"date-parts":[[2025,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The athero-contour: A novel tool for global and rapid assessment of atherogenic parameters. A use case in saroglitazar treatment of MAFLD patients","name":"articletitle","label":"Article Title"},{"value":"Cl\u00ednica e Investigaci\u00f3n en Arteriosclerosis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.arteri.2024.04.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier Espa\u00f1a, S.L.U. on behalf of Sociedad Espa\u00f1ola de Arteriosclerosis.","name":"copyright","label":"Copyright"}],"article-number":"100723"}}